YC-1 (Highly Pure)

Description

YC-1 (Highly Pure)
Catalog number: B2014177
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 2.5 mg
Molecular Weight or Concentration: 304.34 g/mol
Supplied as: Powder
Applications: molecular tool for various biochemical applications
Storage: RT
Keywords: 3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl indazole
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Yu KH, Hung HY. Synthetic strategy and structure-activity relationship (SAR) studies of 3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1, Lificiguat): a review RSC Adv. 2021 Dec 20;12(1):251-264.
2: Ouyang C, Zhang J, Lei X, Xie Z, Liu X, Li Y, Huang S, Wang Z, Tang G. Advances in antitumor research of HIF-1 inhibitor YC-1 and its derivatives Bioorg Chem. 2023 Apr;133:106400.
3: Chun YS, Yeo EJ, Park JW. Versatile pharmacological actions of YC-1: anti-platelet to anticancer Cancer Lett. 2004 Apr 15;207(1):1-7.
4: Hu H, Miao XK, Li JY, Zhang XW, Xu JJ, Zhang JY, Zhou TX, Hu MN, Yang WL, Mou LY. YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1 and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells Eur J Pharmacol. 2020 May 5;874:172961.
5: Harada T, Hirose K, Wada Y, Sato M, Ichise K, Aoki M, Kato T, Takeda K, Takai Y. YC-1 sensitizes the antitumor effects of boron neutron capture therapy in hypoxic tumor cells J Radiat Res. 2020 Jul 6;61(4):524-534.
6: Wu JY, Shih YL, Lin SP, Hsieh TY, Lin YW. YC-1 Antagonizes Wnt/_-Catenin Signaling Through the EBP1 p42 Isoform in Hepatocellular Carcinoma Cancers (Basel). 2019 May 13;11(5):661.
7: Pal B, Kitagawa T. Binding of YC-1/BAY 41-2272 to soluble guanylate cyclase: A new perspective to the mechanism of activation Biochem Biophys Res Commun. 2010 Jul 2;397(3):375-9.
8: Tsui L, Chang SF, Huang HP, Fong TH, Wang IJ. YC-1 induces lipid droplet formation in RAW 264.7 macrophages J Biomed Sci. 2016 Jan 15;23:2.
9: Jin Q, Zheng J, Chen M, Jiang N, Xu X, Huang F. HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib Oxid Med Cell Longev. 2021 Mar 3;2021:6633867.
10: Tulis DA. Salutary properties of YC-1 in the cardiovascular and hematological systems Curr Med Chem Cardiovasc Hematol Agents. 2004 Oct;2(4):343-59.

Products Related to YC-1 (Highly Pure) can be found at Chemicals